MedTrace Logo

Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)

NCT01511523 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-03-16

No results posted yet for this study

Summary

A research study of a compound containing vitamin E, silymarin and carnitine, three over the counter supplements. The investigators hope to learn if the new supplement can safely and successfully treat fatty liver disease or Non Alcoholic Fatty Liver Disease (NAFLD).

Conditions

  • Non Alcoholic Fatty Liver Disease

Interventions

DIETARY_SUPPLEMENT

RGMA001

3 capsules administered BID once a day.

DIETARY_SUPPLEMENT

Sugar Pill

Placebo

Sponsors & Collaborators

  • Biovil Research Group, LLC

    lead INDUSTRY

Principal Investigators

  • John Poulos, MD · Cumberland Research Associates

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01511523 on ClinicalTrials.gov